University of Groningen
ADPKD
Messchendorp, Annemarie Lianne
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Messchendorp, A. L. (2019). ADPKD: Risk Prediction for Treatment Selection. Rijksuniversiteit Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
ADPKD
Risk Prediction for Treatment Selection
A. Lianne Messchendorp | ADPKD - Risk Prediction for Treatment Selection
ISBN: 978-94-6375-264-0 (printed version) 978-94-6375-283-1 (digital version)
Financial support by the University Medical Center Groningen, Research institute GUIDE, University of Groningen for the publication of this thesis is gratefully acknowledged.
Financial support for the printing of this thesis was also kindly provided by:
Cover design: Marije Esselink, Studio Neon
ADPKD
Risk Prediction for Treatment Selection
Proefschrift
ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties.
De openbare verdediging zal plaatsvinden op maandag 25 februari 2019 om 14.30 uur
door
Annemarie Lianne Messchendorp
geboren op 12 oktober 1988 te Groningen
Promotores
Prof. dr. R.T. Gansevoort Prof. dr. C.A.J.M. Gaillard
Beoordelingscommissie
Prof. dr. H.J. Lambers Heerspink Prof. dr. J.W. de Fijter
TABLE OF CONTENTS
1. Introduction 7
2. Estimation of total kidney volume in autosomal dominant polycystic kidney disease
21
3. T1 vs. T2 weighted magnetic resonance imaging to assess total kidney volume in patients with autosomal dominant polycystic kidney disease
47
4. Urinary biomarkers to identify ADPKD patients with a high likelihood of disease progression
69
5. Urinary biomarkers to select patients with rapidly progressive autosomal dominant polycystic kidney disease
99
6. Kidney Function Reserve Capacity in early and later stage autosomal dominant polycystic kidney disease
127
7. Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease
161
8. Somatostatin in renal physiology and the place of somatostatin analogues in autosomal dominant polycystic kidney disease
183
9. Effect of a somatostatin analogue on the vasopressin pathway in patients with autosomal dominant polycystic kidney disease
207
10. Recommendations for the use of tolvaptan in ADPKD: a proposal to update the ERA-EDTA decision algorithm
225
11. General discussion and future perspectives 247
Nederlandse samenvatting 265
Dankwoord 277
